Baylor

Baylor College of Medicine teams with Luna to expand access to in-home, outpatient physical therapy services

Retrieved on: 
Tuesday, November 7, 2023

NASHVILLE, Tenn., Nov. 7, 2023 /PRNewswire/ -- Baylor College of Medicine , a renowned health sciences institution in Houston, Texas, has teamed up with Luna , the leading provider of in-home outpatient physical therapy, to expand access to patient services.

Key Points: 
  • NASHVILLE, Tenn., Nov. 7, 2023 /PRNewswire/ -- Baylor College of Medicine , a renowned health sciences institution in Houston, Texas, has teamed up with Luna , the leading provider of in-home outpatient physical therapy, to expand access to patient services.
  • Residents across Houston will have access to convenient, high-quality outpatient physical therapy in the safety and convenience of their own home.
  • "Patient access is a big concern for us, given our limited number of outpatient physical therapy clinics.
  • Working together with Luna allows Baylor to expand patient access to physical therapy and other specialities care without the need for additional brick-and-mortar locations," said Gayleen Breeding, administrator of orthopedic surgery at Baylor.

Ultima Genomics to Present at ASHG and Provide Updated Reference Data Set

Retrieved on: 
Tuesday, October 31, 2023

Watchmaker Genomics will demonstrate gene fusion detection via cost-effective whole transcriptome sequencing using the optimized Watchmaker RNA Library prep kit.

Key Points: 
  • Watchmaker Genomics will demonstrate gene fusion detection via cost-effective whole transcriptome sequencing using the optimized Watchmaker RNA Library prep kit.
  • In conjunction with the conference, Ultima will be releasing a new data set demonstrating significant improvements to the technology made through early access.
  • In particular, the data demonstrates significant improvements in indel accuracy made through a variety of advancements across chemistry and bioinformatics.
  • Industry Education Session: Empowering Genomics at Scale Thursday, Nov. 2 | Room 140AB | Talks 3:30 - 4:30 p.m.

Agendia® Names Joyce A. O'Shaughnessy, MD as New Principal Investigator for FLEX Study

Retrieved on: 
Tuesday, October 10, 2023

IRVINE, Calif. and AMSTERDAM, Oct. 10, 2023 /PRNewswire/ -- Agendia®, Inc., a global leader in innovative genomic technology and diagnostic tests, announced today that Dr. Joyce A. O'Shaughnessy, MD has been appointed as the new National Principal Investigator for the FLEX Study, a real-world, large-scale, prospective, observational breast cancer study (NCT03053193) intended to enable the discovery of novel gene expression profiles, through the capture of whole transcriptome and extensive clinical data, to expand knowledge and improve precision in the management of breast cancer.

Key Points: 
  • Dr. O'Shaughnessy is board certified in both internal medicine as well as medical oncology and focuses her practice and clinical research on breast cancer treatment.
  • To date, more than 14,000 patients have been successfully enrolled in the FLEX Study, with representation of various ages, races, ethnicities, and health statuses.
  • "We are honored to have Dr. Joyce O'Shaughnessy join our efforts as the National Principal Investigator for the landmark FLEX Study.
  • For more information about Agendia and the FLEX Study, visit www.agendia.com and follow Agendia on Facebook , Twitter ,  and LinkedIn .

Baylor Genetics Announces Neurodevelopmental Disorders Test Panel to Help Healthcare Providers Diagnose Patients with Intellectual Disabilities or Developmental Delays

Retrieved on: 
Tuesday, September 12, 2023

The panel analyzes a clinically curated and targeted set of 236 genes to help healthcare providers and patients achieve a prompt, accurate genetic diagnosis and a better understanding of prognosis and anticipated disease progression.

Key Points: 
  • The panel analyzes a clinically curated and targeted set of 236 genes to help healthcare providers and patients achieve a prompt, accurate genetic diagnosis and a better understanding of prognosis and anticipated disease progression.
  • Baylor Genetics leveraged its genetic expertise and robust datasets to create the Neurodevelopmental Disorders Panel, which joins a growing catalog of disease-specific panels.
  • The panel is performed on an exome backbone capable of extracting a specific subset of genes for clinical reporting.
  • If panel results are negative, healthcare providers may request Whole Exome Sequencing allowing for broader analysis to help make a genetic diagnosis.

U.S. News & World Report Names Baylor St. Luke's Medical Center Among Best Hospitals for Cardiology, Heart & Vascular Surgery, Diabetes & Endocrinology, Gastroenterology & GI Surgery, Geriatrics, Neurology & Neurosurgery, and Urology

Retrieved on: 
Tuesday, August 1, 2023

"It is a privilege to again see the work of our expert caregivers and staff earn recognition as a Best Hospital by U.S.

Key Points: 
  • "It is a privilege to again see the work of our expert caregivers and staff earn recognition as a Best Hospital by U.S.
  • "Baylor St. Luke's Medical Center continues to perform well in the Best Hospital rankings compiled by U.S. News & World Report," said Dr. Paul Klotman, President, CEO and executive dean of Baylor College of Medicine.
  • Baylor faculty and clinical leaders are paramount to the success of the hospital, and I thank them for their efforts."
  • In addition, the following St. Luke's Health hospitals earned "High Performing" ratings for the following procedures and conditions:

Baylor Genetics Announces Epilepsy Panel

Retrieved on: 
Tuesday, July 11, 2023

HOUSTON, July 11, 2023 (GLOBE NEWSWIRE) -- Baylor Genetics , a clinical diagnostic laboratory at the forefront of genetic testing and precision medicine, today announced the availability of an Epilepsy Panel and a STAT Epilepsy Panel - with the latter intended for patients with new onset or change in seizure frequency or character.

Key Points: 
  • HOUSTON, July 11, 2023 (GLOBE NEWSWIRE) -- Baylor Genetics , a clinical diagnostic laboratory at the forefront of genetic testing and precision medicine, today announced the availability of an Epilepsy Panel and a STAT Epilepsy Panel - with the latter intended for patients with new onset or change in seizure frequency or character.
  • In addition to epilepsy, seen in the setting of syndromic disorders, the Baylor Genetics Epilepsy Panel offers an analysis of well-studied, actionable genes related to many non-syndromic epilepsy disorders.
  • Healthcare providers should consider ordering Baylor Genetics’ Epilepsy Panel for patients with syndromic or non-syndromic epilepsy of a suspected genetic origin.
  • Visit our convenient online ordering portal to order the new Epilepsy Panel or STAT Epilepsy Panel today.

MNA Nurses at Boston's Tufts Medical Center Overwhelmingly Vote in Favor of Ratifying New 18-Month Contract Agreement

Retrieved on: 
Thursday, June 29, 2023

BOSTON, June 29, 2023 /PRNewswire/ -- The 1,400 registered nurses of Tufts Medical Center in Boston, who are represented by the Massachusetts Nurses Association, voted overwhelmingly on Monday, June 26 to ratify their newest contract settlement. The 18-month agreement brings with it highly competitive wage increases, an extremely desirable Baylor Plan intended to help recruit nurses to work weekend shifts, and an incentive plan for nurses who commit to working 48 hours per week for 12 weeks.

Key Points: 
  • But it's also because nurses can very easily go elsewhere right now and find work with better pay and benefits.
  • When you have better pay and benefits, you can attract new nurses and keep existing nurses.
  • We want new nurses to come to Tufts and we want our experienced nurses to stay at Tufts, and as a result, our patients will benefit," added Havlicek Cornacchia.
  • The overall length of this contract is also viewed as a benefit by Tufts nurses.

Walden Security Awards 2023 Employee Family Scholarships

Retrieved on: 
Wednesday, May 31, 2023

CHATTANOOGA, Tenn., May 31, 2023 (GLOBE NEWSWIRE) -- Since the Walden Security Employee Family Scholarship was established in 2009, more than $300,000 has been awarded in scholarships.

Key Points: 
  • CHATTANOOGA, Tenn., May 31, 2023 (GLOBE NEWSWIRE) -- Since the Walden Security Employee Family Scholarship was established in 2009, more than $300,000 has been awarded in scholarships.
  • The Employee Family Scholarship awards scholarships to all eligible children and dependents of Walden Security employees who are attending an accredited higher education institution for full-time status the following year.
  • The Walden Security Employee Family Scholarship was established by Walden Security CEO Amy Walden and President Mike Walden to help ease the financial responsibility of their employees’ children’s higher education.
  • “Walden Security has achieved its success with the help of our valued employees,” Amy Walden said.

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Retrieved on: 
Wednesday, May 31, 2023

The multiTAA-specific T cell product used in the TACTAL study was directed against five antigens and showed more durable clinical responses.

Key Points: 
  • The multiTAA-specific T cell product used in the TACTAL study was directed against five antigens and showed more durable clinical responses.
  • Prior to starting the clinical trial Marker assessed the killing capacity of MT-601 in vitro in a lymphoma cell line and demonstrated that MT-601 kills lymphoma cells regardless of their CD19 expression levels.
  • Data from a lymphoma cell line utilizing this model demonstrated that MT-601 inhibited growth of lymphoma cells as well as the growth of CD19 CAR resistant lymphoma cells,” said Eric A. Smith, Ph.D., Director of Research and Development at Marker Therapeutics.
  • While the CAR T cells significantly controlled lymphoma cell growth, we observed that 3 weeks after the start of anti-CD19 CAR T cell administration, a population of lymphoma cells that were resistant to CD19 CAR T cell administration started to grow.

Baylor Genetics Announces Neuromuscular Disorders Panel

Retrieved on: 
Monday, May 22, 2023

In addition to panel testing, Baylor Genetics offers Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) -- two of the most comprehensive precision diagnostic tests -- backed by expert clinical support for actionable treatment guidance. WES is used to understand the cause of a patient's symptoms (phenotypes) or a disease, especially when faced with a nonspecific presentation that may not be captured in a single panel. It provides insights into all genes in the human body, ensuring a full understanding of most genetic disorders. WGS takes this a step further, providing insights into the entire human genome, including the regions between genes. This extensive analysis can significantly increase diagnostic yield over all other types of genetic testing, empowering physicians and patients to make the most informed decisions about future care, family planning, or clinical trial eligibility.

Key Points: 
  • HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- Baylor Genetics , a clinical diagnostic laboratory at the forefront of genetic testing and precision medicine, today announced the availability of a Neuromuscular Disorders Panel (NGS Panel) .
  • Hereditary neuromuscular disorders can be difficult to accurately diagnose based on phenotype alone because of their inherent genetic heterogeneity.
  • Baylor Genetics’ Neuromuscular Disorders Panel assesses many genes based on a clinical indication to help clinicians and their patients achieve an accurate diagnosis sooner and have a better understanding of the prognosis and anticipated disease progression.
  • Visit our convenient online ordering portal to order the new Neuromuscular Disorders Panel today.